Concurrent with the evidence that immunotherapies are beneficial in breast cancer treatment, years of studies with thousands of patients have consistently showed that for early stage HER2+ and TNBC cases the presence and increased numbers of TIL are associated with better disease prognosis and response to therapy [24]. This evidence concerns the gene ERBB2 and breast cancer.